GlassScriptPhysician profile
Payam Benson
NPI 1457539850
$11,870.28
in general payments reported to CMS, 2019-2025
16 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $14.78 · 2021: $388 · 2022: $899 · 2023: $6,586 · 2024: $1,179 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,670 · Travel and Lodging: $1,566 · Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,670.00 |
| Travel and Lodging | $1,565.72 |
| Food and Beverage | $905.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $9,574.74 | 2023-2025 | Veklury |
| Janssen Pharmaceuticals, INC | $428.63 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $405.25 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $249.51 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $234.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $171.21 | 2019-2022 | |
| Abbott Laboratories | $150.00 | 2024 | Freestyle Libre 3 |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Ascendis Pharma Endocrinology INC | $125.00 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Bioxcel Therapeutics, INC. | $115.26 | 2024 | Igalmi |
| Abbvie INC. | $91.31 | 2021-2025 | |
| Mylan Specialty L.P. | $32.93 | 2021-2022 | |
| Pfizer INC. | $15.10 | 2025 | |
| Allergan, INC. | $14.93 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.